Johnny Cheng appointed as interim CEO of HUTCHMED

by | 27th Aug 2025 | News

HUTCHMED has announced that Weiguo Su, CEO of the company, will take a leave of absence from his duties due to health reasons. As a result, the board of directors has appointed Johnny Cheng, an executive director and chief financial officer (CFO) of the company, as acting CEO with immediate effect, in addition to his […]

HUTCHMED has announced that Weiguo Su, CEO of the company, will take a leave of absence from his duties due to health reasons. As a result, the board of directors has appointed Johnny Cheng, an executive director and chief financial officer (CFO) of the company, as acting CEO with immediate effect, in addition to his role as CFO.

“The board has full confidence in Johnny’s capabilities to lead the company and is confident that all research, development and commercial initiatives will remain on track,” said Dan Eldar, chairman and non-executive director. We thank him for his agreement to assume responsibility for overseeing the day-to-day operations and management of the company during this interim period.

“I would like to thank everyone for their support and look forward to being able to return to work as soon as possible,” commented Weiguo Su, CEO. “I am certain that the board, Mr Cheng and everyone at HUTCHMED will ensure the continued execution of our strategy.”

HUTCHMED specialises in the discovery, development and commercialisation of therapies and immunotherapies for cancer and immunological diseases. It was established in China and has expanded internationally since, with therapies approved in China, the US, Europe and Japan.

Tags


Related posts